Renibus announced that their drug RBT-1 was tested in a large clinical trial to see if it could help reduce complications after heart surgery. The trial involved 433 patients across 34 locations in the U.S. and Canada. Researchers gave RBT-1 as a single infusion shortly before non-emergency cardiac surgery and monitored the patients for complications for up to 60 days after the procedure. However, the results showed that RBT-1 did not meet its main goal of significantly reducing serious complications like death or kidney injury.

This research is important for anyone facing heart surgery, especially if you have risk factors like chronic kidney disease. While the overall trial results were not statistically significant, there may be potential benefits for patients at higher risk of complications. About 70% of the trial participants were considered low-risk, which could mean that the drug might be more effective for those with greater health challenges.

The study is still in the early stages of analysis, and while RBT-1 was found to be safe for most patients, some experienced mild side effects. Renibus plans to further investigate the data to determine the next steps for RBT-1’s development. For now, if you or someone you know is preparing for cardiac surgery, it’s worth discussing with your healthcare provider about any new treatments that may be beneficial, especially if you have existing health risks.

Source: longevity.technology